
|Videos|April 21, 2022
Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
2
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
3
Pelareorep Exhibits Activity in Second-Line KRAS-Mutated Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
5





























































































